NYSE:AZN - AstraZeneca Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $37.16 +0.20 (+0.54 %) (As of 07/16/2018 06:32 AM ET)Previous Close$36.96Today's Range$36.6950 - $37.1852-Week Range$28.43 - $37.30Volume5.22 million shsAverage Volume3.28 million shsMarket Capitalization$94.12 billionP/E Ratio8.68Dividend Yield3.69%Beta0.6 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Receive AZN News and Ratings via Email Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:AZN CUSIPN/A Webwww.astrazeneca.com Phone44-20-3749-5000 Debt Debt-to-Equity Ratio1.08 Current Ratio0.73 Quick Ratio0.54 Price-To-Earnings Trailing P/E Ratio8.68 Forward P/E Ratio22.39 P/E Growth1.99 Sales & Book Value Annual Sales$22.47 billion Price / Sales4.19 Cash Flow$3.3387 per share Price / Cash11.13 Book Value$6.57 per share Price / Book5.66 Profitability EPS (Most Recent Fiscal Year)$4.28 Net Income$3.00 billion Net Margins12.61% Return on Equity30.73% Return on Assets7.44% Miscellaneous Employees61,100 Outstanding Shares2,532,900,000Market Cap$94,122.41 AstraZeneca (NYSE:AZN) Frequently Asked Questions What is AstraZeneca's stock symbol? AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN." How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca? AstraZeneca declared a semiannual dividend on Monday, February 5th. Shareholders of record on Friday, February 16th will be given a dividend of $0.95 per share on Monday, March 19th. This represents a yield of 5.62%. The ex-dividend date is Thursday, February 15th. View AstraZeneca's Dividend History. When did AstraZeneca's stock split? How did AstraZeneca's stock split work? AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split. How were AstraZeneca's earnings last quarter? AstraZeneca plc (NYSE:AZN) announced its quarterly earnings results on Friday, May, 18th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.20. The company earned $5.18 billion during the quarter, compared to analyst estimates of $5.24 billion. AstraZeneca had a net margin of 12.61% and a return on equity of 30.73%. The firm's quarterly revenue was down 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.99 earnings per share. View AstraZeneca's Earnings History. When is AstraZeneca's next earnings date? AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for AstraZeneca. What guidance has AstraZeneca issued on next quarter's earnings? AstraZeneca updated its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.46. What price target have analysts set for AZN? 17 equities research analysts have issued 12 month price objectives for AstraZeneca's stock. Their predictions range from $35.00 to $42.00. On average, they expect AstraZeneca's share price to reach $38.2833 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Ratings for AstraZeneca. What is the consensus analysts' recommendation for AstraZeneca? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting AstraZeneca? AstraZeneca saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 7,144,897 shares, a decrease of 34.8% from the June 15th total of 10,959,514 shares. Based on an average daily volume of 3,577,564 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.3% of the shares of the stock are sold short. View AstraZeneca's Current Options Chain. Who are some of AstraZeneca's key competitors? Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG). Who are AstraZeneca's key executives? AstraZeneca's management team includes the folowing people: Mr. Pascal Soriot, Exec. Director & CEO (Age 59)Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)Mr. Jefrey Pott, Gen. CounselMs. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer Has AstraZeneca been receiving favorable news coverage? Press coverage about AZN stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AstraZeneca earned a news sentiment score of 0.12 on Accern's scale. They also assigned media coverage about the company an impact score of 46.06 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are AstraZeneca's major shareholders? AstraZeneca's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.52%), BLB&B Advisors LLC (0.00%), Raymond James Trust N.A. (0.00%), Fulton Bank N.A. (0.00%), Gofen & Glossberg LLC IL (0.00%) and Catawba Capital Management VA (0.00%). View Institutional Ownership Trends for AstraZeneca. Which institutional investors are selling AstraZeneca stock? AZN stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A., Gofen & Glossberg LLC IL, Atria Investments LLC and Raymond James Trust N.A.. View Insider Buying and Selling for AstraZeneca. Which institutional investors are buying AstraZeneca stock? AZN stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, BLB&B Advisors LLC, Catawba Capital Management VA, RDL Financial Inc. and Private Trust Co. NA. View Insider Buying and Selling for AstraZeneca. How do I buy shares of AstraZeneca? Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AstraZeneca's stock price today? One share of AZN stock can currently be purchased for approximately $37.16. How big of a company is AstraZeneca? AstraZeneca has a market capitalization of $94.12 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe. How can I contact AstraZeneca? AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected] MarketBeat Community Rating for AstraZeneca (NYSE AZN)Community Ranking: 1.9 out of 5 ()Outperform Votes: 542 (Vote Outperform)Underperform Votes: 910 (Vote Underperform)Total Votes: 1,452MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?